Filed March 13, 2026

Serial No. 99701154

Examining Attorney null

Class engineered nucleic acid sequences for medical purposes; nucleases, fusion proteins, RNAs and biomolecular complexes for modification of cellular genome; gene editing agents for modifying RNA sequences; gene editing agents for modifying DNA sequences at genomic target sites; engineered biomolecular complexes comprised of fusion proteins and RNAs used for modifying nucleic acid sequences in human genomes; engineered biomolecular compound for enhanced regulation and correction of gene expression and mutations, excision and insertion of DNA sequences, and delivery of whole genes and nucleic acid sequences to target sites; gene therapy and cell therapy products in the nature of DNA editing complexes targeting genomic sites; 005; 006; 018; 044; 046; 051; 052; 100; 103; 106; 100; 101

Case Type Trademark Service mark